Aventis/TKT Dynepo

BLA for gene-activated erythropoietin will be resubmitted in about six months, firms estimate. The BLA submitted Aug. 2 has been withdrawn while the companies collect additional process validation data following an increase in manufacturing scale from 2,000 liter to 5,000 liter bioreactors